A prospective, randomized clinical trial comparing plasmakinetic resection of the prostate with holmium laser enucleation: 2-year follow up, "Beyond the Abstract," by Yanbo Chen

BERKELEY, CA (UroToday.com) - Our hospital is the largest HoLEP (holmium laser enucleation of the prostate) centre in Shanghai, China, and each year we treat 300 to 400 HoLEP patients. Employing the modified enucleation and morcellation technique for treating benign prostatic hyperplasia (BPH), HoLEP enucleation has become a routine technique in my department, and its long learning curve has been shortened. Thus, our technique has begun to spread rapidly in Shanghai.

In our centre, we also have bipolar and monopolar TURP (transurethral resection of prostate) systems, however, compared with them, HoLEP techniques have broadened the scope of minimally-invasive treatment for BPH. Thus, patients with large-sized prostates or those taking oral anticoagulants are no longer considered contraindications.

Based on our wealth of experience with the surgical treatment of BPH as well as our long-term study of patient follow up, we consider HoLEP to be the most promising technique to replace the current “gold standard,” TURP.

 

Written by:
Yanbo Chen as part of Beyond the Abstract on UroToday.com. This initiative offers a method of publishing for the professional urology community. Authors are given an opportunity to expand on the circumstances, limitations etc... of their research by referencing the published abstract.

Department of Urology and Andrology, Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, and Department of Urology, General Hospital of Ningxia Medical University, Yinchuan (LMM), China

A prospective, randomized clinical trial comparing plasmakinetic resection of the prostate with holmium laser enucleation of the prostate based on a 2-year followup - Abstract

More Information about Beyond the Abstract